Published in J Virol on October 01, 1996
Severe adenovirus pneumonia in immunocompetent adults: a case report and review of the literature. Eur J Clin Microbiol Infect Dis (2008) 1.85
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol (2007) 1.70
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol (2000) 1.60
In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol (1998) 1.45
Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol (2000) 1.17
Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. J Virol (2003) 1.11
Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol (2005) 1.00
Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol (2008) 0.95
Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections. Antimicrob Agents Chemother (2005) 0.94
Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica (2010) 0.88
Pulmonary immunity to viral infection: adenovirus infection of lung dendritic cells renders T cells nonresponsive to interleukin-2. J Virol (2006) 0.87
Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation. Adv Hematol (2013) 0.87
Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol (1999) 0.87
New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Curr Opin Investig Drugs (2010) 0.83
Fell Pony syndrome: characterization of developmental hematopoiesis failure and associated gene expression profiles. Clin Vaccine Immunol (2012) 0.78
Prostaglandin E2 Production and T Cell Function in Mouse Adenovirus Type 1 Infection following Allogeneic Bone Marrow Transplantation. PLoS One (2015) 0.78
The promise and potential hazards of adenovirus gene therapy. Gut (2001) 0.78
Helper-Dependent Adenoviral Vectors. J Genet Syndr Gene Ther (2011) 0.75
Adenoviral Vectors for Hemophilia Gene Therapy. J Genet Syndr Gene Ther (2013) 0.75
Contributions of CD8 T cells to the pathogenesis of mouse adenovirus type 1 respiratory infection. Virology (2017) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Processing of adenovirus 2-induced proteins. J Virol (1973) 12.52
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
Proliferating dendritic cell progenitors in human blood. J Exp Med (1994) 7.67
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04
Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med (1989) 5.65
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med (1994) 5.28
Human adenovirus-host cell interactions: comparative study with members of subgroups B and C. J Virol (1990) 4.32
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet (1994) 3.56
Worldwide epidemiology of human adenovirus infections. Am J Epidemiol (1983) 3.45
Genetic variability of adenoviruses. Ann N Y Acad Sci (1980) 2.91
Multiple adenovirus serotypes use alpha v integrins for infection. J Virol (1994) 2.86
Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol (1995) 2.41
Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A (1995) 2.33
Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol (1991) 2.16
Characterization of human proliferative T cell responses to adenovirus. J Infect Dis (1995) 2.15
Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology (1991) 2.00
Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol (1995) 1.88
Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med (1995) 1.78
Phylogenetic relationships among adenovirus serotypes. Virology (1994) 1.73
Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J Virol (1992) 1.71
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother (1995) 1.71
The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology (1992) 1.71
Latent adenovirus infections of the human respiratory tract. Am J Hyg (1958) 1.62
Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis (1994) 1.57
Association of human class I MHC alleles with the adenovirus E3/19K protein. J Immunol (1994) 1.30
Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1A is immunodominant in H-2b, but not in H-2d or H-2k mice. J Immunol (1991) 1.29
Detection of adenovirus nucleic acid sequences in human tonsils in the absence of infectious virus. Virus Res (1987) 1.28
Getting the inside out: the transporter associated with antigen processing (TAP) and the presentation of viral antigen. Proc Natl Acad Sci U S A (1995) 1.16
The murine cellular immune response to adenovirus type 5. Immunol Cell Biol (1989) 1.10
Molecular mechanisms by which adenoviruses counteract antiviral immune defenses. Crit Rev Immunol (1990) 1.09
Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood (1994) 1.02
Endogenous expression of E1A in human cells enhances the effect of adenovirus E3 on class I major histocompatibility complex antigen expression. J Virol (1993) 0.91
Resistance of human cells to the adenovirus E3 effect on class I MHC antigen expression. Implications for antiviral immunity. J Immunol (1990) 0.91
Human T cell proliferative response to polypeptides from adenovirus type 2. J Infect Dis (1995) 0.89
Identification of adenovirus E1A regions which affect MHC class I expression and susceptibility to cytotoxic T lymphocytes. Virology (1995) 0.87
Anti-adenovirus type 5 cytotoxic T lymphocytes: immunodominant epitopes are encoded by the E1A gene. J Virol (1991) 0.84
E1A gene expression induces susceptibility to killing by NK cells following immortalization but not adenovirus infection of human cells. Virology (1995) 0.82
Mutations in the adenovirus-encoded single-stranded DNA binding protein that result in altered accumulation of early and late viral RNAs. Virology (1995) 0.78
Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J (1989) 5.93
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med (1996) 4.07
The structure of adenovirus 2 early nuclear and cytoplasmic RNAs. J Mol Biol (1980) 2.74
Loop structures in hybrids of early RNA and the separated strands of adenovirus DNA. Proc Natl Acad Sci U S A (1977) 2.60
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia (2010) 2.22
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood (2001) 2.20
Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med (1996) 2.10
Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol (1990) 1.97
Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature (1985) 1.86
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood (1998) 1.86
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother (1995) 1.71
Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. J Natl Cancer Inst (1986) 1.69
Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer (1985) 1.62
Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer (1986) 1.62
New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol (1987) 1.58
Donor T cells to treat EBV-associated lymphoma. N Engl J Med (1994) 1.53
Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet (1993) 1.53
Characterization of mutations in the gene doublecortin in patients with double cortex syndrome. Ann Neurol (1999) 1.47
Young adults with arthritis: meeting their transitional needs. Br J Rheumatol (1996) 1.44
Transmembrane orientation of glycoproteins encoded by the v-fms oncogene. Cell (1985) 1.41
Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer (1984) 1.37
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood (2000) 1.37
Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther (1998) 1.34
Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev (1997) 1.33
The interleukin-10 homolog encoded by Epstein-Barr virus enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer cell responses. Virology (1992) 1.17
Modification-deficient transfer ribonucleic acids from relaxed control Escherichia coli: structures of the major undermodified phenylalanine and leucine transfer RNAs produced during leucine starvation. Biochemistry (1977) 1.17
Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant (2007) 1.12
Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther (2000) 1.11
Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation (2001) 1.08
Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma. IARC Sci Publ (1985) 1.06
Rearrangement of immunoglobulin heavy chain genes in T cell acute lymphoblastic leukemia. Blood (1985) 1.06
Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology (1995) 1.05
Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant (2007) 1.05
Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer (2001) 1.04
Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology (1994) 1.00
Childhood acute lymphoblastic leukemia with chromosomal breakpoints at 11q23. Blood (1989) 0.96
Sequence of the DNA-binding protein of a human subgroup E adenovirus (type 4): comparisons with subgroup A (type 12), subgroup B (type 7), and subgroup C (type 5). Virology (1985) 0.96
T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci (2005) 0.96
Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther (1998) 0.96
Localization of adenovirus-encoded DNA replication proteins in the nucleus by immunogold electron microscopy. J Gen Virol (1990) 0.95
Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res (1999) 0.94
Transfection and gene expression in normal and malignant primary B lymphocytes. J Immunol Methods (1990) 0.92
Unique phenylalanine transfer ribonucleic acids in relaxed control Escherichia coli: genetic origin and some functional properties. Biochemistry (1976) 0.92
Unbalanced growth and the production of unique transfer ribonucleic acids in relaxed-control Escherichia coli. J Bacteriol (1975) 0.89
Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood (1991) 0.89
Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity. Blood (1988) 0.89
Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. Blood (1990) 0.89
Biologic and prognostic significance of the presence of more than two mu heavy-chain genes in childhood acute lymphoblastic leukemia of B precursor cell origin. Blood (1986) 0.89
Biochemical analysis of adenovirus type 5 DNA-binding protein mutants. J Biol Chem (1989) 0.88
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.87
mRNA transcripts initiating within the human immunoglobulin mu heavy chain enhancer region contain a non-translatable exon and are extremely heterogeneous at the 5' end. Nucleic Acids Res (1991) 0.87
Functional analysis of the adenovirus type 5 DNA-binding protein: site-directed mutants which are defective for adeno-associated virus helper activity. J Virol (1986) 0.87
Suicide genes as safety switches in T lymphocytes. Cytotherapy (2003) 0.87
Conserved region 3 of the adenovirus type 5 DNA-binding protein is important for interaction with single-stranded DNA. J Virol (1990) 0.85
Restriction mapping and molecular cloning of adenovirus type 4 (subgroup E) DNA. Gene (1982) 0.85
Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol (2002) 0.85
Anti-interleukin-10 antibodies in patients with chronic active Epstein-Barr virus infection. J Infect Dis (1997) 0.85
Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol (1986) 0.82
In vivo maturation of an undermodified Escherichia coli leucine transfer RNA. Biochem Biophys Res Commun (1976) 0.82
Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma (1996) 0.82
Bidirectional transcription from the human immunoglobulin VH6 gene promoter. Nucleic Acids Res (1994) 0.81
14q32 translocations are associated with mixed-lineage expression in childhood acute leukemia. Blood (1990) 0.81
Temperature-sensitive mutants of adenovirus single-stranded DNA-binding protein. Inability to support DNA replication is associated with an altered DNA-binding activity of the protein. J Biol Chem (1991) 0.81
Sequence of the DNA-binding protein gene of a human subgroup B adenovirus (type 7). Comparisons with subgroup C (type 5) and subgroup A (type 12). J Biol Chem (1984) 0.80
Provocative pattern of rearrangements of the genes for the gamma and beta chains of the T-cell receptor in human leukemias. Proc Natl Acad Sci U S A (1987) 0.80
Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia (1998) 0.80
The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Leuk Lymphoma (1996) 0.80
Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant (1996) 0.79
Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol (2013) 0.79
Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher (1999) 0.78
NK cells can recognize asialylated autologous lymphocytes and ABO-mismatched lymphocytes. Immunology (1984) 0.78
Alterations in immunoglobulin or T cell receptor gene rearrangement at relapse: involvement of 11q23 and changes in immunophenotype. Leukemia (1990) 0.78
Gene marking after bone marrow transplantation. Eur J Cancer (1994) 0.78
Isolation of activated ras transforming genes from two patients with Hodgkin's disease. Int J Radiat Oncol Biol Phys (1985) 0.78
Wild-type p53 induction mediated by replication-deficient adenoviral vectors. Cancer Res (1999) 0.78
Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy (2002) 0.78
Epstein-Barr infection after bone marrow transplantation. Blood (1994) 0.78
T cell therapies. Ernst Schering Found Symp Proc (2006) 0.78
Clonal analysis of childhood acute lymphoblastic leukemia with "cytogenetically independent" cell populations. J Clin Invest (1989) 0.78
Analysis of the imperfect octamer-containing human immunoglobulin VH6 gene promoter. Nucleic Acids Res (1994) 0.77
Characterization of immunoglobulin heavy chain genes from an acute lymphocytic leukemia with four rearrangements. Leukemia (1991) 0.77
The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. Leuk Lymphoma (2000) 0.77
Inhibition of post-transcriptional modification of E. coli tRNA. Brookhaven Symp Biol (1975) 0.77
Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy (2003) 0.77
Functional changes in temperature-sensitive mutants of the adenovirus single-stranded DNA-binding protein are accompanied by structural alterations. J Virol (1992) 0.77
Sequencing of selected regions of the human immunoglobulin heavy-chain gene locus that completes the sequence from JH through the delta constant region. DNA Seq (1991) 0.76
Mixed lineage leukemia: the implications for hematopoietic differentiation. Blood (1986) 0.76
Use of gene marking in bone marrow transplantation. Cancer Detect Prev (1996) 0.76
Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol (1999) 0.75
Differential activation of cytotoxic responses by Burkitt's lymphoma (BL)-cell lines: relationship to the BL-cell surface phenotype. Cell Immunol (1986) 0.75
Transition from paediatric to adult care. Bridging the gaps or passing the buck? Arch Dis Child (2000) 0.75
Endemic and sporadic cases of Epstein-Barr virus-positive Burkitt's lymphoma: immunological characterization of derived cell lines. Haematol Blood Transfus (1985) 0.75
Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences. Cancer Res (1993) 0.75
Expression of a novel surface antigen MKW in childhood acute leukemia has prognostic significance. Leukemia (1991) 0.75
Options for T-cell based therapies. Vox Sang (2004) 0.75
Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications. Cytokines Mol Ther (1995) 0.75
Detection of minimal residual disease in all: biology, methods, and applications. Cancer Treat Res (1996) 0.75
General and specific effects of amino acid starvation on the formation of undermodified Escherichia coli phenylalanine tRNA. Biochim Biophys Acta (1976) 0.75